Home Online Features Avertix's Guardian System Confirmed as Cost-Effective for High-Risk Acute Coronary Syndrome Patients
Avertix’s Guardian System Confirmed as Cost-Effective for High-Risk Acute Coronary Syndrome Patients
Hand-out
Press Releases
Avertix Medical  
February 14, 2025

Avertix’s Guardian System Confirmed as Cost-Effective for High-Risk Acute Coronary Syndrome Patients

EATONTOWN, N.J., Feb. 14, 2025 /PRNewswire/ -- Avertix Medical, Inc. ("Avertix" or the "Company"), the developer of The Guardian® system - the world's first real-time, continuous heart attack detection and

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social